Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
#BladderCancer
#blcsm
#uroonc
#utuc
biomarker
bladder cancer
cytology MCM5
follow-up
non-muscle-invasive bladder cancer
surveillance
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
pubmed:
4
8
2020
medline:
27
4
2021
entrez:
4
8
2020
Statut:
ppublish
Résumé
To compare directly the performance of the ADXBLADDER test with that of cytology in the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences. ADXBLADDER is a urine test based on the detection of MCM5, a DNA licensing factor expressed in all cells capable of dividing. Expression is usually restricted to the basal stem cell compartment; however, in malignancy, MCM5-expressing cells can be found throughout the epithelium. Detection of MCM5 in urine sediment can be indicative of the presence of a bladder tumour. A multicentre prospective, blinded study was carried out from August 2017 and July 2019 at 21 European Union centres, 14 of which collected matching cytology data. Urine was collected from patients prior to cystoscopy. Urine cytology and ADXBLADDER were performed and compared to the diagnosis obtained by cystoscopy. The performance of cytology and ADXBLADDER were then compared. The overall performance of ADXBLADDER demonstrated a sensitivity of 51.9%, a specificity of 66.4%, and a negative predictive value (NPV) of 92%. The sensitivity of ADXBLADDER for low- and high-grade recurrences was 44.1% and 58.8%, respectively. By contrast, cytology sensitivity was 16.7%, specificity was 98% and NPV was 90.7%. Cytology sensitivity for both low- and high-grade disease was 17.6%. ADXBLADDER detection of both low- and high-grade NMIBC recurrence is superior to that of cytology, with ADXBLADDER able to exclude the presence of high-grade recurrence in 97.8% of cases compared to 97.1% with cytology. These results show that ADXBLADDER has promise as a more reliable alternative to urine cytology in the follow-up of NMIBC.
Sections du résumé
OBJECTIVE
To compare directly the performance of the ADXBLADDER test with that of cytology in the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences.
BACKGROUND
ADXBLADDER is a urine test based on the detection of MCM5, a DNA licensing factor expressed in all cells capable of dividing. Expression is usually restricted to the basal stem cell compartment; however, in malignancy, MCM5-expressing cells can be found throughout the epithelium. Detection of MCM5 in urine sediment can be indicative of the presence of a bladder tumour.
PATIENTS AND METHODS
A multicentre prospective, blinded study was carried out from August 2017 and July 2019 at 21 European Union centres, 14 of which collected matching cytology data. Urine was collected from patients prior to cystoscopy. Urine cytology and ADXBLADDER were performed and compared to the diagnosis obtained by cystoscopy. The performance of cytology and ADXBLADDER were then compared.
RESULTS
The overall performance of ADXBLADDER demonstrated a sensitivity of 51.9%, a specificity of 66.4%, and a negative predictive value (NPV) of 92%. The sensitivity of ADXBLADDER for low- and high-grade recurrences was 44.1% and 58.8%, respectively. By contrast, cytology sensitivity was 16.7%, specificity was 98% and NPV was 90.7%. Cytology sensitivity for both low- and high-grade disease was 17.6%.
CONCLUSIONS
ADXBLADDER detection of both low- and high-grade NMIBC recurrence is superior to that of cytology, with ADXBLADDER able to exclude the presence of high-grade recurrence in 97.8% of cases compared to 97.1% with cytology. These results show that ADXBLADDER has promise as a more reliable alternative to urine cytology in the follow-up of NMIBC.
Identifiants
pubmed: 32745350
doi: 10.1111/bju.15194
pmc: PMC7891338
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
198-204Subventions
Organisme : Arquer DIagnostics Ltd
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Références
Int J Med Sci. 2017 Jul 19;14(9):811-819
pubmed: 28824318
Urology. 2003 Jan;61(1):109-18; discussion 118
pubmed: 12559279
Urol Oncol. 2018 Aug;36(8):361.e1-361.e6
pubmed: 29859728
World J Urol. 2018 Dec;36(12):1981-1995
pubmed: 29931526
Bladder Cancer. 2018 Oct 29;4(4):353-363
pubmed: 30417046
Eur Urol Oncol. 2020 Aug;3(4):548-554
pubmed: 31331861
Science. 1945 May 18;101(2629):519-20
pubmed: 17775845
Lancet. 1999 Oct 30;354(9189):1524-5
pubmed: 10551502
Urol Oncol. 2017 Aug;35(8):531.e15-531.e22
pubmed: 28366272
J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9
pubmed: 12122098
BJU Int. 2019 Aug;124(2):251-257
pubmed: 30281893
Eur Urol Oncol. 2020 Feb;3(1):42-46
pubmed: 31307961
PLoS One. 2012;7(7):e40305
pubmed: 22792272
Adv Anat Pathol. 2016 Jul;23(4):193-201
pubmed: 27233050
Am J Clin Pathol. 2007 Feb;127(2):295-301
pubmed: 17210520